ECHODIA

Their core work

ECHODIA is a small French private company that contributed as an industry partner to two consecutive Marie Skłodowska-Curie glaucoma research training networks (EGRET and EGRET-Plus). In the MSCA framework, industry SMEs typically provide PhD researchers with secondments, hands-on equipment access, and applied research exposure — suggesting ECHODIA brings a practical, device or instrumentation angle to ophthalmic or diagnostic research. Their company name hints at a diagnostics focus ("echo" + "dia"), and their location near Clermont-Ferrand places them in a French medtech cluster. However, the absence of keywords or project descriptions in the CORDIS record means their exact technical contribution cannot be confirmed from this data alone.

What they specialise in

How they've shifted over time

Both H2020 projects sit within a narrow 2015–2020 window and cover the same subject area — European glaucoma research training — so there is no observable topic shift in this dataset. What is visible is a progression in engagement depth: ECHODIA entered as a non-funded third party in EGRET (2015) and returned as a funded participant receiving over EUR 262,000 in EGRET-Plus (2016), suggesting the consortium valued their contribution enough to formalize and fund it. Without keyword data for either project, tracking any finer thematic evolution within their glaucoma-related work is not possible from this record.

ECHODIA's move from unpaid partner to funded participant within the same programme family suggests they are building toward a recognized industry training role, but with only two projects spanning a single topic, it is too early to identify a broader strategic direction.

How they like to work

ECHODIA has never led a project — both participations are as a partner or participant within large MSCA training consortia. With 14 unique consortium partners across 6 countries for just two closely related projects, their network is wide but topic-specific, shaped by the EGRET consortium rather than independently built. This points to a company that enters collaboration through existing research networks rather than initiating its own consortia.

ECHODIA has worked with 14 unique partners across 6 countries, a number that reflects the size of the EGRET training consortia rather than independent network-building. Their collaborative footprint is entirely within MSCA research training structures, and geographically spans multiple European countries typical of ITN and COFUND networks.

What sets them apart

ECHODIA occupies a narrow but genuine niche as a French SME with repeat participation in the leading European glaucoma research training programme — a signal that the academic consortium found sustained value in their industry-side contribution. For consortium builders assembling an MSCA or health research bid with an ophthalmic or diagnostic dimension, ECHODIA offers documented experience in this specific collaboration format. However, their profile is thin: two projects, one topic, no coordinator experience, and no public keywords — so due diligence on their actual capabilities is essential before engaging.

Highlights from their portfolio

• EGRET-Plus
  ECHODIA received EUR 262,876 as a funded participant in this MSCA-ITN-ETN network, making it their only funded H2020 project and the clearest evidence of a substantive, valued industry role within a pan-European glaucoma training consortium.
• EGRET
  ECHODIA's entry point into European research collaboration — as a non-funded third party in the original European Glaucoma Research Training Program, establishing the relationship that led to their funded role in EGRET-Plus.